Albuminar® 5,
Albuminar® 20,
Albuminar® 25
Albumin (Human) U.S.P. 5% Solution, 20% Solution, and 25% Solution
Albumin (Human) 25% is indicated in the emergency treatment of shock due to burns, trauma, operations, and infections; in the treatment of severe injuries; and in other similar conditions where the restoration of blood volume is urgent.
- Natural plasma protein product
- Safe and effective therapy for over 50 years
Broad Therapeutic Applications
- Plasma expansion and replacement - trauma, burns, and shock
- Conditions where restoration of blood volume is urgent
- Hypoproteinemia
Safety at the Source
- Source plasma screening for human immunodeficiency virus (HIV) 1 and 2 and for other vial indicators, including markers for hepatitis B virus and hepatitis C virus
- 100% of plasma comes from repeat donors, who are routinely tested at the time of each donation
Effective Viral Inactivation
- Pasteurization (heat treatment in aqueous solution) at 60°C for 10 hours - a demonstrated viral inactivation method that inactivates lipid-enveloped and certain non-lipid-enveloped viruses
NDC Number |
Product Description |
| 0053-7680-32 |
50 mL |
| 0053-7680-33 |
100 mL |
Important Safety Information
Albuminar® is contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.
Albuminar® is derived from human plasma, as with all plasma-derived products, the risk of transmission of infectious agents, including viruses, and theoretically, the Creutzfeldt-Jakob (CJD) disease agent, cannot be completely eliminated. As with any pharmaceutical, the physician should weigh the risks and benefits of administration.
Please see the
full prescribing information for Albuminar® 5.
Please see the
full prescribing information for Albuminar® 20.
Please see the
full prescribing information for Albuminar® 25.
View universal billing codes for Albuminar®
CUSTOMER SUPPORT 1-800-683-1288 or
Customer Services
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
Last Updated: 04 August 2011